{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T08:48:44Z","timestamp":1777798124508,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019110","name":"Tessa Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP210027"],"award-info":[{"award-number":["RP210027"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jtct.2024.09.009","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T07:07:04Z","timestamp":1726124824000},"page":"1193.e1-1193.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-2532","authenticated-orcid":false,"given":"Ibrahim N.","family":"Muhsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9014-7538","authenticated-orcid":false,"given":"Kristen E.","family":"Shaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1957-7160","authenticated-orcid":false,"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengfen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7707-2331","authenticated-orcid":false,"given":"Premal","family":"Lulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4004-7837","authenticated-orcid":false,"given":"Carlos A.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rammurti T.","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7049-7698","authenticated-orcid":false,"given":"Helen E.","family":"Heslop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Carrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-935X","authenticated-orcid":false,"given":"LaQuisa C.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2024.09.009_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-017-0180-z","article-title":"Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation","volume":"7","author":"Styczynski","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.009_bib0002","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haematopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2024.09.009_bib0003","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2024.09.009_bib0004","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","article-title":"Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy","volume":"12","author":"George","year":"2010","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.009_bib0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jtct.2024.09.009_bib0006","first-page":"12","article-title":"Risk factors for cytomegalovirus infection after allogeneic hematopoietic cell transplantation in malignancies: proposal for classification","volume":"37","author":"Dziedzic","year":"2017","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.jtct.2024.09.009_bib0007","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/v15061358","article-title":"An update on current antiviral strategies to combat human cytomegalovirus infection","volume":"15","author":"Panda","year":"2023","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.009_bib0008","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2165\/00003495-199448030-00009","article-title":"Ganciclovir. An update of its therapeutic use in cytomegalovirus infection","volume":"48","author":"Markham","year":"1994","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jtct.2024.09.009_bib0009","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00003495-199448020-00007","article-title":"Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections","volume":"48","author":"Wagstaff","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.jtct.2024.09.009_bib0010","unstructured":"Prevymis\u00ae (letermovir): United States Food & Drug Adminstration.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209939Orig1s000,209940Orig1s000lbl.pdf. Accessed January 01, 2020."},{"key":"10.1016\/j.jtct.2024.09.009_bib0011","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/IDR.S180908","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review","volume":"12","author":"Helou","year":"2019","journal-title":"Infect Drug Resist"},{"issue":"25","key":"10.1016\/j.jtct.2024.09.009_bib0012","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.009_bib0013","doi-asserted-by":"crossref","first-page":"ofac687","DOI":"10.1093\/ofid\/ofac687","article-title":"Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies","volume":"10","author":"Vyas","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"21","key":"10.1016\/j.jtct.2024.09.009_bib0014","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/bloodadvances.2021005637","article-title":"Letermovir prophylaxis in T-cell depleted transplants: breakthrough and rebound infections in the post marketing setting","volume":"5","author":"Marzolini","year":"2021","journal-title":"Blood Advances"},{"key":"10.1016\/j.jtct.2024.09.009_bib0015","first-page":"419","article-title":"Efficacy of letermovir prophylaxis in cytomegalovirus seropositive allogeneic hematopoietic stem cell transplant recipients receiving in-vivo T-cell depletion","volume":"54","author":"Kodiyanplakkal","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"10.1016\/j.jtct.2024.09.009_bib0016","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.3390\/cancers13215572","article-title":"Letermovir prophylaxis and cytomegalovirus reactivation in adult hematopoietic cell transplant recipients with and without acute graft versus host disease","volume":"13","author":"Wolfe","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jtct.2024.09.009_bib0017","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41409-019-0730-y","article-title":"Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation","volume":"55","author":"Sharma","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2024.09.009_bib0018","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.bbmt.2020.07.002","article-title":"Letermovir prophylaxis decreases burden of cytomegalovirus (CMV) in patients at high risk for CMV disease following hematopoietic cell transplant","volume":"26","author":"Johnsrud","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2024.09.009_bib0019","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/bloodadvances.2021006213","article-title":"Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation","volume":"6","author":"Lorentino","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.09.009_bib0020","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ajh.20780","article-title":"Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab","volume":"82","author":"Cheung","year":"2007","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.009_bib0021","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious complications associated with alemtuzumab use for lymphoproliferative disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2024.09.009_bib0022","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/leu.2008.282","article-title":"Valganciclovir thrice weekly for prophylaxis against cytomegalovirus reactivation during alemtuzumab therapy","volume":"23","author":"Hwang","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jtct.2024.09.009_bib0023","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/blood.V99.12.4357","article-title":"High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution","volume":"99","author":"Chakrabarti","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2024.09.009_bib0024","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/sj.bmt.1705263","article-title":"Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival","volume":"37","author":"Juliusson","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.09.009_bib0025","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2141.2005.05513.x","article-title":"Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma","volume":"129","author":"Kr\u00f6ger","year":"2005","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2024.09.009_bib0026","doi-asserted-by":"crossref","first-page":"682.e1","DOI":"10.1016\/j.jtct.2021.04.020","article-title":"Natural history of Epstein-Barr virus replication and viral load dynamics after alemtuzumab-based allogeneic stem cell transplantation","volume":"27","author":"Marzolini","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2024.09.009_bib0027","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-3083.2011.02530.x","article-title":"The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation","volume":"73","author":"Olkinuora","year":"2011","journal-title":"Scand J Immunol"},{"issue":"23","key":"10.1016\/j.jtct.2024.09.009_bib0028","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724006614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724006614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T03:49:29Z","timestamp":1764560969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724006614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2666636724006614"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.09.009","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}